# First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

> **NCT06934538** · PHASE1,PHASE2 · RECRUITING · sponsor: **Brenus Pharma** · enrollment: 90 (estimated)

## Conditions studied

- Unresectable Metastatic Colorectal Cancer
- Unresectable Locally Advanced Colorectal Cancer

## Interventions

- **BIOLOGICAL:** STC-1010 + IS regimen + SOC therapy

## Key facts

- **NCT ID:** NCT06934538
- **Lead sponsor:** Brenus Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2028-06
- **Final completion:** 2029-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06934538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06934538, "First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06934538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*